Regentis Biomaterials

Board of Directors

Dr. Ehud Geller, Chairman

Dr. Ehud Geller, Chairman - Founder & Managing Partner, Medica Venture Partners

Dr. Ehud Geller has been active in the health care/biopharma and life science industries for over 30 years. The former president and CEO of Interpharm Laboratories, Ltd., he presided over the growth of this company from the seed stage to $18 million in revenues. Prior to that, Dr. Geller, was the president of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, Israel´s largest pharmaceutical company. At Teva he led the merger of the pharmaceutical business involved in the acquisition of Ikapharm Ltd., and the strategy of Teva´s entry into the U.S. market. Earlier, Dr. Geller conducted pharmaceutical research at Wyeth Laboratories in the U.S. Dr. Geller has a B.Sc. degree in chemical engineering, an MBA from Columbia University, and a Ph.D. degree in pharma/chemical engineering from Drexel Institute. He serves as founder and director of biotech and device health care companies.

Mr. Jeff Dykan

Mr. Jeff Dykan - Managing Partner, SCP Vitalife

Mr. Dykan began his career with Andersen Consulting in New York and has over 25 years experience in finance, business development and general management in global growth companies and startups. He has had a lead role in managing investments of Vitalife, including arranging financings. Prior to joining Vitalife, he was Chairman and CEO of BitBand, an IP broadband start up, and held several senior financial positions, including as CFO at VocalTec Communications, as Director of Regional Finance for Applied Materials in Israel and VP Finance at Opal. Mr. Dykan is Chairman of Trig Medical and serves on board of directors of Deep Breeze, Quantomix, BetaO2, Genegrafts, Niti Surgical Solutions and the Technion Incubator. He has a B.S. in accounting and management from New York University and an MBA in computer applications also from New York University. Mr. Dykan is also licensed in New York State as a certified public accountant.

Pieter Wolters

Pieter Wolters - Managing Director DSM Venturing B.V.

Pieter is Managing Director DSM Venturing and Vice President of DSM’s Global Innovation Center. 

DSM Venturing, the corporate venture unit of Royal DSM, is invested in 25+ startup companies across various domains, including Biomedical, Human Nutrition, Solar and Additive Manufacturing.  

Prior to joining DSM Venturing in 2012, Pieter gained fifteen years of operating and commercial experience in the medical space as co-founder and CEO of OrthAlign (2008-2011) and as CEO at IsoTis (1997-2007).  He started his career in 1988 in international M&A, investment management and transaction advisory.  Pieter holds a law degree from Leiden University, NL and is based in Boston, MA.

Pieter serves on the boards of Regentis, Miach Orthopeadics, Bio2 Technologies, LECT, Frontier Nutrition, Interface Biologics and until recently Essential Medical (acquired by Teleflex in September 2018).

Mr. Junmin Wang

Mr. Junmin Wang - President, CEO, Founder of Haisco Pharmaceutical

•Bachelor, Shenyang Pharmaceutical University.
•EMBA, Cheung Kong Graduate School of Business
•DBA, Cheung Kong Graduate School of Business
•EMBA, TsinghuaUniversity
•CEO class, Shanghai Advanced Institute of Finance (SAIF)

With almost 20 years industrial working practice, Mr. Wang has rich experience in pharmaceutical enterprise operation and management, sharp business market sense and a deeper understanding about the pharmaceutical research, development and sales in both domestic and oversea.

Keith C. Valentine, Independent Director

Keith C. Valentine, Independent Director - President, Chief Executive Officer & Director of SeaSpine

Keith C. Valentine serves as President, Chief Executive Officer and as a director of SeaSpine. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc., from 2007 to 2015 and as President from 2004 to 2007, prior to which he served in various senior executive roles in Marketing, Development and Operations since joining the company in 2001. Previously, Mr. Valentine was Vice President of Marketing at ORATEC Interventions, Inc., which was acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including Vice President of Marketing for the Thoracolumbar Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.

Itay Attar, CPA

Itay Attar, CPA - Portfolio Manager, crossroad venture capital

Itay Attar, CPA is the portfolio manager for crossroad venture capital, one of the earliest investors in Regentis. Itay serves as a director in 5 portfolio companies and accumulated broad international diversified experience. Itay is responsible for all aspects of fund management including fundraising, screening, deal sourcing, negotiations, transaction structuring, financial reporting, etc. Itay holds a B.A. in economics and accounting, M.A. in economics, both from Ben Gurion university and currently is a Ph.D. candidate in the department of economics at Ben Gurion University. Itay is also a Certified Public Accountant in Israel